Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07311564 · ClinicalTrials.gov registry record · Phase 2
A Study of LAD603 in Adults With Alopecia Areata
A Phase 2 study of Alopecia Areata, sponsored by Almirall, S.A..
- Recruiting
- Registry status
- Phase 2
- Development phase
- 136
- Enrollment target
- 1
- Study location
NCT07311564 is a Phase 2 study of Alopecia Areata that is actively recruiting participants, run by Almirall, S.A.. The registered enrollment target is 136 participants, below the 1,950-participant average among 26 other Alopecia Areata trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state.
The verdict
NCT07311564, a Phase 2 study of Alopecia Areata, is actively recruiting participants, sponsored by Almirall, S.A..
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 136 participants
- Enrollment target
- 1
- Study location
Study Summary
The main aim of the study is to evaluate the effect of LAD603 in adult participants with severe to very severe alopecia areata (AA). The study will also evaluate the safety, pharmacokinetics (PK), immunogenicity and pharmacodynamic (PD) biomarkers of LAD603.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG LAD603
Study Locations (1)
Nebraska
- Investigator Site 1 - Omaha
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 136 participants |
| Start Date | 2025-12-17 |
| Est. Completion | 2027-11-21 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07311564
The ClinicalTrials.gov registry entry for NCT07311564 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 136 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,950-participant average among 26 other Alopecia Areata trials with a reported enrollment target (93% lower). The listed sponsor is Almirall, S.A., which has 19 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Alopecia Areata appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07311564 reports 1 study location spanning 1 distinct geographic area - top geographies include Nebraska.
Frequently Asked Questions
What is clinical trial NCT07311564 about?
NCT07311564 is a clinical study titled "A Study of LAD603 in Adults With Alopecia Areata". The main aim of the study is to evaluate the effect of LAD603 in adult participants with severe to very severe alopecia areata (AA). The study will also evaluate the safety, pharmacokinetics (PK), immunogenicity and pharmacodynamic (PD) biomarkers of LAD603.
What is the current status of trial NCT07311564?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 136 participants. The study started on 2025-12-17. Estimated completion is 2027-11-21.
What conditions does trial NCT07311564 study?
This clinical trial studies the following conditions: Alopecia Areata.
What interventions are being tested in trial NCT07311564?
The interventions under investigation include: Placebo (OTHER), LAD603 (DRUG).
Who is sponsoring clinical trial NCT07311564?
This trial is sponsored by Almirall, S.A., which has 19 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07311564 being conducted?
This trial has 1 study location across Nebraska. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alopecia Areata
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Evaluation of Microbiota Transplant Therapy in Patients With Alopecia Areata
RECRUITING · Phase 2
-
Dupilumab in the Treatment of Pediatric Alopecia Areata
RECRUITING · Phase 2
-
Evaluate the Efficacy and Safety of Ruxolitinib on Hair Regrowth in Patients With Autoimmune Polyendocrinopathy Candidiasis Ectodermal Dystrophy (APECED)-Associated Alopecia Areata
RECRUITING · Phase 2
-
Treatment of Atopic Dermatitis and Alopecia Areata With Abrocitinib in Individuals With Down Syndrome
RECRUITING · Phase 2
-
Regeneron AA Multicenter (Dupilumab)
RECRUITING · Phase 2
-
A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Severe to Very Severe Alopecia Areata in Adult Patients (Rezolve AA)
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.